ARTICLE | Company News
Biovail, Aventis deal
January 8, 2001 8:00 AM UTC
BVF will pay $409.5 million to AVE's Aventis Pharmaceuticals Inc. (Parsippany, N.J.) for North American rights to Cardizem calcium channel blockers to treat hypertension and angina. BVF paid $239.5 m...